Health Care [ 5/12 ] | Biotechnology [ 33/74 ]
NASDAQ | Common Stock
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer.
The company was founded in 2017 and is headquartered in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 26 | -0.32 Increased by +11.11% | -0.30 Decreased by -7.85% |
| Mar 30, 26 | -0.29 Increased by +14.71% | -0.32 Increased by +9.09% |
| Nov 4, 25 | -0.14 Increased by +48.15% | -0.07 Decreased by -100.00% |
| Aug 5, 25 | -0.35 Decreased by -45.83% | -0.35 |
| May 6, 25 | -0.36 Decreased by -2.86% | -0.35 Decreased by -4.08% |
| Mar 17, 25 | -0.34 Decreased by -6.25% | -0.34 Increased by +0.82% |
| Nov 6, 24 | -0.27 Decreased by -17.39% | -0.37 Increased by +27.03% |
| Aug 7, 24 | -0.24 Decreased by -4.35% | -0.34 Increased by +29.41% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 0.00 Decreased by -100.00% | -45.51 M Decreased by -14.14% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 25 | 0.00 Decreased by -100.00% | -38.75 M Decreased by -2.86% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 53.81 M Increased by +363.61% | 15.88 M Increased by +154.46% | Increased by +29.52% Increased by +111.75% |
| Jun 30, 25 | 3.18 M Decreased by -83.99% | -38.85 M Decreased by -52.06% | Decreased by -1.22 K% Decreased by -850.08% |
| Mar 31, 25 | 5.39 M Decreased by -16.67% | -39.88 M Decreased by -5.17% | Decreased by -739.54% Decreased by -26.22% |
| Dec 31, 24 | 4.12 M Decreased by -24.19% | -37.67 M Decreased by -22.45% | Decreased by -914.99% Decreased by -61.53% |
| Sep 30, 24 | 11.61 M Increased by +8.15% | -29.17 M Decreased by -31.01% | Decreased by -251.29% Decreased by -21.13% |
| Jun 30, 24 | 19.88 M Increased by +36.15% | -25.55 M Decreased by -23.38% | Decreased by -128.56% Increased by +9.38% |